Cellectar Biosciences
CLRB
6 hedge funds and large institutions have $403K invested in Cellectar Biosciences in 2016 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
50% more funds holding
Funds holding: 4 → 6 (+2)
22% less capital invested
Capital invested by funds: $514K → $403K (-$111K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$67K |
| 2 |
Morgan Stanley
New York
|
+$25.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$16.7K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
+$8.37K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$242K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CAM
1
Cormorant Asset Management
Boston,
Massachusetts
| $185K | – | – | – |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $81K | +$67K | +8 | New |
|
|
AIC
3
AWM Investment Company
New York
| $47K | – | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| $35K | +$16.7K | +2 | +200% |
|
|
5
Morgan Stanley
New York
| $29K | +$25.1K | +3 | New |
|
|
6
Creative Planning
Overland Park,
Kansas
| $14K | +$8.37K | +1 | New |
|
|
WAM
7
Wealthspire Advisors (Maryland)
Potomac,
Maryland
| $4K | – | – | – |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $3K | – | – | – |
|
|
BFA
9
BlackRock Fund Advisors
San Francisco,
California
| $2K | – | – | – |
|
|
MFS
10
MSI Financial Services
Springfield,
Massachusetts
| $2K | – | – | – |
|
11
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| $1K | – | – | – |
|
|
SM
12
Sabby Management
Miami Beach,
Florida
| – | -$242K | -24 | Closed |
|
CLRB Hedge Fund Activity: Q2 2016 in Review
6 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q2 2016, worth a combined $403K — down 22% from $514K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new CLRB positions and 1 closed out — a net gain of 2 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $67K. The largest seller was Sabby Management, exiting entirely with an estimated $242K sold.
- 6 institutional investors held Cellectar Biosciences (CLRB) as of Q2 2016, up from 4 in Q1 2016.
- Funds reported $403K of Cellectar Biosciences stock for Q2 2016, down 22% quarter-over-quarter.
- 3 funds opened new Cellectar Biosciences positions in Q2 2016 and 1 closed out, a net change of +2 holders.
- The largest Cellectar Biosciences buyer in Q2 2016 was Vanguard Group, an estimated $67K added.
- The largest Cellectar Biosciences seller in Q2 2016 was Sabby Management, an estimated $242K sold.
Based on aggregated 13F filings for Q2 2016.